Grifols (GRFS) Net Cash Flow Growth (1y) (2011 - 2020)
Grifols (GRFS) Net Cash Flow Growth (1y) (2011 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 195.58% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -0.70% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 349.49% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -55.11% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -517.34% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 78.10% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 75.96% |
| Dec 31, 2019 | -124.72% |
| Mar 31, 2019 | -317.42% |
| Dec 31, 2018 | -72.95% |
| Jun 30, 2018 | -314.28% |
| Mar 31, 2018 | -93.45% |
| Dec 31, 2017 | 6,845.21% |
| Dec 31, 2016 | 94.44% |
| Sep 30, 2016 | -322.73% |
| Dec 31, 2015 | 31.25% |
| Sep 30, 2015 | -95.34% |
| Jun 30, 2015 | 127.10% |
| Mar 31, 2015 | -113.47% |
| Dec 31, 2014 | -474.01% |
| Sep 30, 2014 | 2,956.96% |
| Jun 30, 2014 | -2,467.60% |
| Mar 31, 2014 | 6,719.95% |
| Dec 31, 2013 | 61.60% |
| Sep 30, 2013 | -12.97% |
| Jun 30, 2013 | -62.30% |